Orasis Pharmaceuticals Appoints Industry Veteran, Paul Smith, as President and Chief Operating Officer to Lead the Next Phase of Growth
April 26, 2021 08:00 ET
|
Orasis Pharmaceuticals
HERZLIYA, Israel, April 26, 2021 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the...
Visionary Ventures Closes Fund II with $114MM in Committed Capital
March 23, 2021 09:17 ET
|
Visionary Venture Fund
Aliso Viejo, California, March 23, 2021 (GLOBE NEWSWIRE) -- Visionary Ventures today announced the closing of Visionary Venture Fund II with $114MM in committed capital. The Fund, which was strongly...
Equinox Ophthalmic, Inc. appoints Stuart Raetzman as Executive Chair
October 07, 2020 06:00 ET
|
Equinox Ophthalmic, Inc.
NEWPORT BEACH, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Equinox Ophthalmic, Inc, an early-stage medical device company that is developing a new paradigm to revolutionize the treatment of glaucoma...
Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia
September 10, 2020 09:30 ET
|
Orasis Pharmaceuticals
HERZLIYA, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment...
TearClear Raises $22 Million to Advance Multiple Clinical Programs in Development
August 11, 2020 07:00 ET
|
TearClear Corp.
BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- TearClear has raised $22M in a Series B funding round. The investment will be used to advance multiple clinical programs in development, with two lead...
TearClear appoints Robert J. Dempsey Chief Executive Officer
April 16, 2020 07:30 ET
|
TearClear Corp.
BOSTON, April 16, 2020 (GLOBE NEWSWIRE) -- TearClear, a global Ophthalmic Pharmaceutical Company, today announced the appointment of Robert J. Dempsey as Chief Executive Officer. TearClear is the...
Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopia
October 10, 2019 09:30 ET
|
Orasis Pharmaceuticals
HERZLIYA, Israel, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD., a clinical stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an...
Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia
March 27, 2019 09:14 ET
|
Orasis Pharmaceuticals
HERZLIYA, Israel, March 27, 2019 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD., a clinical stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an...
Orasis Announces Appointments of Richard L. Lindstrom, Eric D. Donnenfeld, and John Berdahl to its Scientific Advisory Board
November 27, 2018 08:00 ET
|
Orasis Pharmaceuticals
HERZLIYA, Israel, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD., a clinical stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an...
Orasis Announces the Appointment of Jeffry Weinhuff as Chairman of the Board of Directors
October 22, 2018 08:00 ET
|
Orasis Pharmaceuticals
HERZLIYA, Israel, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD. a clinical-stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an...